Vogenx Initiates Phase 2b EMERGE Study of Mizagliflozin for Post-Bariatric ...
(PR-inside.com) Randomized, double-blind, placebo-controlled trial will evaluate two doses of the first-in-class, minimally absorbed SGLT1 inhibitor in patients with recurrent hypoglycemia following bariatric surgery RALEIGH, NC / ACCESS Newswire / October 15, 2026 / Vogenx, Inc. (NASDAQ:VOGX), a clinical-stage develop…
Solo un extracto — este editor licencia su texto. Lea el comunicado completo en la fuente.
Plan Gratis · Plus 29 CA$ o Pro 99 CA$/mes


